View in EDS HTML Full Text PDF Full Text

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.

Saved in:
Bibliographic Details
Title: Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Authors: Brunner AM; Massachusetts General Hospital, Boston, Massachusetts, USA., Esteve J; Hospital Clínic, Barcelona, Spain., Porkka K; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Knapper S; School of Medicine, Cardiff University, Cardiff, UK., Traer E; Oregon Health & Science University, Portland, Oregon, USA., Scholl S; University Hospital Jena, Jena, Germany., Garcia-Manero G; MD Anderson Cancer Center, Houston, Texas, USA., Vey N; Institut Paoli-Calmettes, Marseille, France., Wermke M; TU Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany., Janssen JJWM; Amsterdam University Medical Centers, Amsterdam, The Netherlands., Narayan R; Massachusetts General Hospital, Boston, Massachusetts, USA., Fleming S; The Alfred Hospital, Melbourne, Victoria, Australia., Loo S; The Alfred Hospital, Melbourne, Victoria, Australia., Tovar N; Hospital Clínic, Barcelona, Spain., Kontro M; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Ottmann OG; School of Medicine, Cardiff University, Cardiff, UK., Naidu P; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Sun H; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Han M; Cure Ventures, Boston, Massachusetts, USA., White R; Novartis Ireland Limited, Dublin, Ireland., Zhang N; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Mohammed A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Sabatos-Peyton CA; Larkspur Biosciences, Cambridge, Massachusetts, USA., Steensma DP; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Rinne ML; Blueprint Medicines, Cambridge, Massachusetts, USA., Borate UM; Oregon Health & Science University, Portland, Oregon, USA., Wei AH; The Peter MacCallum Cancer Centre and Royal Melbourne Hospital Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Source: American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. E32-E36. Date of Electronic Publication: 2023 Nov 22.
Publication Type: Clinical Trial, Phase I; Letter; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37994196
AccessLevel: 2
PubType: Report
PubTypeId: report
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Brunner+AM%22">Brunner AM</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Esteve+J%22">Esteve J</searchLink>; Hospital Clínic, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Porkka+K%22">Porkka K</searchLink>; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Knapper+S%22">Knapper S</searchLink>; School of Medicine, Cardiff University, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Traer+E%22">Traer E</searchLink>; Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Scholl+S%22">Scholl S</searchLink>; University Hospital Jena, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Garcia-Manero+G%22">Garcia-Manero G</searchLink>; MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Vey+N%22">Vey N</searchLink>; Institut Paoli-Calmettes, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Wermke+M%22">Wermke M</searchLink>; TU Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Janssen+JJWM%22">Janssen JJWM</searchLink>; Amsterdam University Medical Centers, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Narayan+R%22">Narayan R</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Fleming+S%22">Fleming S</searchLink>; The Alfred Hospital, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Loo+S%22">Loo S</searchLink>; The Alfred Hospital, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Tovar+N%22">Tovar N</searchLink>; Hospital Clínic, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Kontro+M%22">Kontro M</searchLink>; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Ottmann+OG%22">Ottmann OG</searchLink>; School of Medicine, Cardiff University, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Naidu+P%22">Naidu P</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Sun+H%22">Sun H</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Han+M%22">Han M</searchLink>; Cure Ventures, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22White+R%22">White R</searchLink>; Novartis Ireland Limited, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Zhang+N%22">Zhang N</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Mohammed+A%22">Mohammed A</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Sabatos-Peyton+CA%22">Sabatos-Peyton CA</searchLink>; Larkspur Biosciences, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Steensma+DP%22">Steensma DP</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Rinne+ML%22">Rinne ML</searchLink>; Blueprint Medicines, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Borate+UM%22">Borate UM</searchLink>; Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Wei+AH%22">Wei AH</searchLink>; The Peter MacCallum Cancer Centre and Royal Melbourne Hospital Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227610369%22">American journal of hematology</searchLink> [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. E32-E36. <i>Date of Electronic Publication: </i>2023 Nov 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Letter; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7610369 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203618609%22">03618609 </searchLink><i>NLM ISO Abbreviation: </i>Am J Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37994196
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ajh.27161
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: E32
    Titles:
      – TitleFull: Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brunner AM
      – PersonEntity:
          Name:
            NameFull: Esteve J
      – PersonEntity:
          Name:
            NameFull: Porkka K
      – PersonEntity:
          Name:
            NameFull: Knapper S
      – PersonEntity:
          Name:
            NameFull: Traer E
      – PersonEntity:
          Name:
            NameFull: Scholl S
      – PersonEntity:
          Name:
            NameFull: Garcia-Manero G
      – PersonEntity:
          Name:
            NameFull: Vey N
      – PersonEntity:
          Name:
            NameFull: Wermke M
      – PersonEntity:
          Name:
            NameFull: Janssen JJWM
      – PersonEntity:
          Name:
            NameFull: Narayan R
      – PersonEntity:
          Name:
            NameFull: Fleming S
      – PersonEntity:
          Name:
            NameFull: Loo S
      – PersonEntity:
          Name:
            NameFull: Tovar N
      – PersonEntity:
          Name:
            NameFull: Kontro M
      – PersonEntity:
          Name:
            NameFull: Ottmann OG
      – PersonEntity:
          Name:
            NameFull: Naidu P
      – PersonEntity:
          Name:
            NameFull: Sun H
      – PersonEntity:
          Name:
            NameFull: Han M
      – PersonEntity:
          Name:
            NameFull: White R
      – PersonEntity:
          Name:
            NameFull: Zhang N
      – PersonEntity:
          Name:
            NameFull: Mohammed A
      – PersonEntity:
          Name:
            NameFull: Sabatos-Peyton CA
      – PersonEntity:
          Name:
            NameFull: Steensma DP
      – PersonEntity:
          Name:
            NameFull: Rinne ML
      – PersonEntity:
          Name:
            NameFull: Borate UM
      – PersonEntity:
          Name:
            NameFull: Wei AH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2024 Feb
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1096-8652
          Numbering:
            – Type: volume
              Value: 99
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: American journal of hematology
              Type: main
ResultId 1